Further to my last blog, I've continued updating and consolidating the shareholdings within my SIPP. This continues to be (generally) in-line with the criteria I have set myself when reviewing SIPP performance earlier this year, ie:-
1) Investment companies to have a market value of greater than £500 million
2) Investment companies to have a yield of at least 3%.
3) Investment companies to be without significant debt, or able to cover debt from cash reserves (if this does not make sense that is because I am NOT a trained financial analyst).
I have been able to finance the purchases by monthly contributions to the SIPP (£750 per month) and from the sale of my entire shareholding in International Personal Finance (IPF) whose share price has recently spiked to 425+, and by trimming my shareholding in Fidelity Asian Value IT (FAS).
The current shareholdings are as follows:
1) BlackRock Smaller Co IT (BRSC) : 894 shares
3) GlaxoSmithKline (GSK) : 620 shares
5) Hill & Smith Holdings (HILS) : 375 shares
7) International Personal Finance (IPF) : SOLD
19) Cenkos (CNKS) : 870 shares
Financial Data for SIPP
Target at 31st December 2014 = £86,000
36 months @ £300 = £10,800
Total = £13,050
Capital Growth = £89,896 less (£51,684.02 + £13,050) = £25,152 or 39%